Top Story

Hispanic veterans with HCV at higher risk for cirrhosis, HCC

September 1, 2014

Hispanic veterans with hepatitis C virus infection had a higher risk for developing cirrhosis or hepatocellular carcinoma compared with African-American and non-Hispanic white patients, according to new study results.

Researchers, including Hashem B. El-Serag, MD, MSHS, and Fasiha Kanwal, MD, MSHS, of Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, Houston, collected and analyzed data from 149,407 patients (mean age, 52.5 years) in the Veterans Administration HCV Clinical Case Registry database between 2000 and 2009. All patients had active hepatitis C virus (HCV) viremia; 56.3% were non-Hispanic whites, 36.1% were African-Americans, 6% were Hispanic, and 1.6% were of other races.

In the Journals

Surgery remains ‘gold standard’ for basal cell carcinoma

September 1, 2014
Surgery remains the ideal treatment for patients with basal cell carcinoma, according to results of an evidence review.Researchers with Columbia University Medical…
FDA News

FDA lifts clinical hold on vantictumab for NSCLC, breast cancer, pancreatic cancer

August 31, 2014
OncoMed Pharmaceuticals recently announced that the FDA has removed the partial clinical hold on enrollment in phase 1 clinical trials for the company’s monoclonal…
Industry News

Growth estimated in B-cell NHL treatment market value

August 30, 2014
The market value of B-cell non-Hodgkin’s lymphoma treatments will experience moderate growth across six major markets from $4.59 billion in 2013 to $5.41 billion…
More News Headlines »
CME CNE

Treatment Decision-Making through the Spectrum of MDS: Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

8/20/2014
MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
Meeting News Coverage Video
figure

Docetaxel plus ADT improved OS in metastatic prostate cancer

June 24, 2014
CHICAGO — Donald L. Trump, MD, FACP, president and CEO at Roswell Park Cancer Institute and HemOnc Today
More »
CME

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

8/16/2014
Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »